Hemophilia is a genetic disorder where the body fails to coagulate blood when blood vessel is ruptured. Between itsvariants, hemophilia A is more common than hemophilia B. A very rare form of hemophilia namely acquired hemophilia results from abnormalities in immune system of an individual. Acquired hemophilia is not a genetic disorder. Common symptoms of hemophilia are internal and external bleeding episodes.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1937
Based on the treatment of hemophilia, global hemophilia therapeutics market is segmented as follows:
- Hemophilia A
- Hemophilia B
The global hemophilia market is further segmented on the basis of medicines used in its treatment which are as follows:
In addition, many market players are focusing on development of gene therapy, not only to treat hemophilia but to cure the disease completely. Apart from octocog Alfa, nonacog Alfa, desmopressin, many drugs are currently in pipeline and upcoming approval of these pipeline drugs will drive the hemophilia therapeutics market towards growth in the near future. Lack of awareness about the disease and available treatment and high cost of available drugs are the major factors that are restraining the growth of the global hemophilia therapeutics market.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453